MX338758B - Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. - Google Patents
Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.Info
- Publication number
- MX338758B MX338758B MX2012010406A MX2012010406A MX338758B MX 338758 B MX338758 B MX 338758B MX 2012010406 A MX2012010406 A MX 2012010406A MX 2012010406 A MX2012010406 A MX 2012010406A MX 338758 B MX338758 B MX 338758B
- Authority
- MX
- Mexico
- Prior art keywords
- human
- seq
- cells
- derived
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
Abstract
La presente invención se refiere a un anticuerpo monoclonal contra el virus de la influenza A, que comprende una cadena liviana que comprende una región CDR1 que comprende una secuencia de SEQ ID NO.7, una región CDR2 que comprende una secuencia de SEQ ID NO. 2, y una región CDR3 que comprende una secuencia de SEQ ID NO.8; y una cadena pesada que comprende una región CDR1 que comprende una secuencia de SEQ ID NO.9; una región CDR2 que comprende una secuencia de SEQ ID NO. 10, SEQ ID NO. 10 y una región CDR3 que comprende una secuencia de SEQ ID NO. 11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100020587 | 2010-03-08 | ||
| PCT/KR2011/001563 WO2011111966A2 (en) | 2010-03-08 | 2011-03-07 | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012010406A MX2012010406A (es) | 2012-10-03 |
| MX338758B true MX338758B (es) | 2016-04-29 |
Family
ID=44563977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010406A MX338758B (es) | 2010-03-08 | 2011-03-07 | Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9573991B2 (es) |
| EP (3) | EP2860190A3 (es) |
| JP (1) | JP5795340B2 (es) |
| KR (1) | KR101297784B1 (es) |
| CN (1) | CN102791734B (es) |
| AU (2) | AU2011225044B2 (es) |
| CA (2) | CA2849668A1 (es) |
| EA (2) | EA201400855A1 (es) |
| IL (1) | IL221760A (es) |
| MX (1) | MX338758B (es) |
| WO (1) | WO2011111966A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| HK1200102A1 (en) * | 2011-09-20 | 2015-07-31 | 西奈山医学院 | Influenza virus vaccines and uses thereof |
| JP5998222B2 (ja) * | 2011-09-30 | 2016-09-28 | セルトリオン・インコーポレイテッド | ヒトｂ細胞で生産されたインフルエンザａウイルス中和活性を持つ結合分子 |
| KR20130059721A (ko) * | 2011-11-29 | 2013-06-07 | (주)셀트리온 | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 |
| JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Ａ型インフルエンザに特異的な抗体 |
| WO2013089496A1 (ko) * | 2011-12-15 | 2013-06-20 | (주)에이프로젠 | H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9834594B2 (en) * | 2012-09-07 | 2017-12-05 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
| JP6386465B2 (ja) | 2012-11-13 | 2018-09-05 | ジェネンテック， インコーポレイテッド | 抗ヘマグルチニン抗体及び使用方法 |
| NZ627796A (en) | 2012-12-18 | 2017-07-28 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| JPWO2015025900A1 (ja) * | 2013-08-23 | 2017-03-02 | 学校法人藤田学園 | 抗インフルエンザウイルス中和抗体 |
| CA2929557C (en) * | 2013-11-07 | 2023-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free nucleic acids for the analysis of the human microbiome and components thereof |
| WO2015082600A1 (en) * | 2013-12-05 | 2015-06-11 | Crucell Holland B.V. | Process for preparing influenza vaccines |
| WO2016010160A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 抗インフルエンザウイルス抗体及びその利用 |
| US20180008702A1 (en) | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
| WO2016089181A1 (ko) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물 |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| EP3247389A4 (en) | 2015-01-23 | 2019-10-30 | Icahn School of Medicine at Mount Sinai | INFLUENZAVIRUSSCHUTZIMPFPLÄNE |
| US9890206B2 (en) * | 2015-08-20 | 2018-02-13 | Medigen Biotechnology Corporation | H1N1 flu virus neutralizing antibodies |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| EP3419663A1 (en) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| EP3498263B1 (en) | 2016-08-10 | 2023-11-29 | Celltrion Inc. | Stable liquid pharmaceutical preparation for anti-influenza virus antibody |
| US20180169780A1 (en) * | 2016-12-19 | 2018-06-21 | Anvil International, Llc | Cleanline threader |
| CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| TWI688653B (zh) * | 2018-01-30 | 2020-03-21 | 長庚醫療財團法人林口長庚紀念醫院 | 人源抗腸病毒７１型單株抗體的製法、產物及其應用 |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| CN112839673A (zh) | 2018-07-23 | 2021-05-25 | 日本国立感染症研究所所长代表之日本国 | 包含流感疫苗的组合物 |
| KR20200060969A (ko) * | 2018-11-23 | 2020-06-02 | (주)셀트리온 | 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법 |
| JP7545955B2 (ja) | 2019-03-04 | 2024-09-05 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| CA3132521A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3137160A1 (en) | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| EP4212548A4 (en) | 2020-09-08 | 2024-04-17 | Novelgen Co., Ltd. | ANTIVIRAL COMPOSITION AGAINST INFLUENZA A VIRUS |
| CN119060174B (zh) * | 2024-09-23 | 2026-04-24 | 中国科学院微生物研究所 | 针对人流感病毒神经氨酸酶的单克隆抗体、其制备方法及应用 |
| CN120965865B (zh) * | 2025-10-15 | 2026-01-16 | 内蒙古盛健生物科技有限责任公司 | 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007089753A2 (en) * | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| EP2059532B1 (en) * | 2006-09-07 | 2012-12-26 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| BRPI0819971A2 (pt) * | 2007-12-06 | 2017-06-27 | Burnham Institute For Medical Res | anticorpos contra vírus influenza e métodos de seu uso |
| EP2274334A2 (en) * | 2008-03-28 | 2011-01-19 | Sea Lane Biotechnologies,llc. | Neutralizing molecules to viral antigens |
| CA2733218A1 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
-
2011
- 2011-03-07 CA CA2849668A patent/CA2849668A1/en not_active Abandoned
- 2011-03-07 AU AU2011225044A patent/AU2011225044B2/en not_active Ceased
- 2011-03-07 WO PCT/KR2011/001563 patent/WO2011111966A2/en not_active Ceased
- 2011-03-07 US US13/583,529 patent/US9573991B2/en active Active
- 2011-03-07 JP JP2012556968A patent/JP5795340B2/ja active Active
- 2011-03-07 EP EP14181741.1A patent/EP2860190A3/en not_active Withdrawn
- 2011-03-07 EP EP11753571.6A patent/EP2545074A4/en not_active Withdrawn
- 2011-03-07 EA EA201400855A patent/EA201400855A1/ru unknown
- 2011-03-07 EP EP16175875.0A patent/EP3098236A1/en active Pending
- 2011-03-07 EA EA201201116A patent/EA021977B1/ru not_active IP Right Cessation
- 2011-03-07 CA CA2790949A patent/CA2790949C/en active Active
- 2011-03-07 MX MX2012010406A patent/MX338758B/es active IP Right Grant
- 2011-03-07 CN CN201180013223.6A patent/CN102791734B/zh active Active
- 2011-03-07 KR KR1020110020061A patent/KR101297784B1/ko active Active
-
2012
- 2012-09-03 IL IL221760A patent/IL221760A/en active IP Right Grant
-
2013
- 2013-07-19 AU AU2013207641A patent/AU2013207641B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011111966A2 (en) | 2011-09-15 |
| MX2012010406A (es) | 2012-10-03 |
| IL221760A (en) | 2016-07-31 |
| AU2011225044B2 (en) | 2013-08-22 |
| CA2790949C (en) | 2017-08-01 |
| CA2790949A1 (en) | 2011-09-15 |
| EP3098236A1 (en) | 2016-11-30 |
| US20130004505A1 (en) | 2013-01-03 |
| CA2849668A1 (en) | 2011-09-15 |
| EA201201116A1 (ru) | 2013-03-29 |
| US9573991B2 (en) | 2017-02-21 |
| EP2545074A4 (en) | 2014-01-08 |
| CN102791734B (zh) | 2014-10-15 |
| EP2545074A2 (en) | 2013-01-16 |
| AU2013207641B2 (en) | 2016-01-14 |
| EP2860190A2 (en) | 2015-04-15 |
| CN102791734A (zh) | 2012-11-21 |
| WO2011111966A3 (en) | 2012-04-05 |
| KR20110102198A (ko) | 2011-09-16 |
| EA201400855A1 (ru) | 2014-11-28 |
| EP2860190A3 (en) | 2015-07-15 |
| EA021977B1 (ru) | 2015-10-30 |
| JP5795340B2 (ja) | 2015-10-14 |
| KR101297784B1 (ko) | 2013-08-20 |
| JP2013527749A (ja) | 2013-07-04 |
| AU2011225044A1 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| CY1123145T1 (el) | Anti-cd40 αντισωματα | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| MX354101B (es) | FORMULACION PARA ANTICUERPO ANTI -A4ß7. | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| MX337060B (es) | Proceso para preparar una composicion de inmunoglobulina. | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20110345A1 (es) | Anticuerpos contra la il17 humana | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| PE20140195A1 (es) | Composiciones de anticuerpo y metodos de uso | |
| WO2012040562A3 (en) | Novel hiv-1 broadly neutralizing antibodies | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| MX2014001374A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| CR20120577A (es) | Anticuerpos hacia gdf8 humano | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX2013009151A (es) | Inmunoterapia mejorada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |